Close Menu

NEW YORK (GenomeWeb) – Abbott today announced the US Food and Drug Administration approved its RealTime CMV molecular test, the only commercially available cytomegalovirus test that can amplify two select regions of the CMV genome, according to the company.

The dual target capability of the assay reduces the risk of underquantitation or failure to detect the virus, a known concern with CMV infections because of possible mutations of the virus, Abbott said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.

Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.

A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.

In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.